2023 European Society for Medical Oncology (ESMO) Congress – October 20-24, 2023 / Madrid, Spain
Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
AVENANCE: Subgroup Analysis of Patients with Advanced First-Line Maintenance
Barthélémy | Poster #2379P
Clinical Characteristics and Survival of Patients with Advanced Merkel Cell Carcinoma (MCC) Treated with Avelumab: Analysis of a Prospective German MCC Registry (MCC TRIM)
Becker | Poster #1145P
Avelumab as Second-Line or Later Treatment in Patients with Metastatic Merkel Cell Carcinoma: Real-World Treatment Patterns in France
Blom | Poster #1148P
Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Cancer: Treatment Patterns and Real-World Outcomes in the US
Carson | Poster #2387P
TOGETHER: Pooled Real-World Datasets of METex14 Skipping NSCLC and Adjusted Comparison of Upfront (Chemo-)Immunotherapy With Tepotinib From VISION
Christopoulos | Poster #1381P
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From the JAVELIN Bladder 100 Trial in Older Patients
Gupta | Poster #2371P
First-Line Treatment Patterns and Overall Survival of Patients With Advanced Merckel Cell Carcinoma in England From 2013-2022: Results of a Nationwide Observational Cohort Study
Knott | Poster #1147P
Safety of Tepotinib + EGFR TKI (osimertinib or gefitinib) in Patients With EGFRm NSCLC
Nadal | Poster #1358P
Factors Associated With Not Receiving Systemic Treatment in Patients with Metastatic Urothelial Carcinoma: Results of a Retrospective Observational Study in Germany
Niegisch | Poster #2386P
Liquid Biopsies (LBx) and Tissue Biopsies (TBx) for Identifying MET Exon 14 Skipping (METex14) in Advanced NSCLC: Analyses From the Phase II VISION Study of Tepotinib
Rolfo | Poster #1382P
Real-World Survival Outcomes and Survival Risk Factors in Elderly Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Saba | Poster #932P
Split-Dose Cisplatin Plus Gemcitabine Use and Associated Clinical Outcomes in the First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer: Results of an Observational Study in Germany (CONVINCE)
Schlack | Poster #2388P
Perceived Unmet Needs and Challenges Faced by Patients with Advanced Bladder Cancer and Their Caregivers: Results of a Social Media Listening Study Conducted in 5 European Countries
Schuck | Poster #2381P
Treatment (Tx) Sequencing With Tepotinib in Previously Treated Patients (Pts) With MET Exon 14 (METex14) Skipping NSCLC in the VISION Trial
Viteri | Poster #1380P
This site is intended for US healthcare professionals only.
DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.
US-MULNP-00023 09/24
By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.
We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content.
These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.
These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.
Help us direct you to the right information by selecting one of the following options: